Cefaly for Migraine Prevention
Are you looking for a more natural yet effective treatment for migraine attacks? In early March 2014, the FDA approved for use a transcutaneous electrical nerve stimulation device for the prevention of a migraine, called Cefaly.
Because of the FDA approval, numerous news outlets have been reporting on the schedule of the gadget, and multiple patients have been asking about the effectiveness of the device and whether it is best for them.
Understanding of the device and the studies done to obtain FDA approval may assist patients and doctors decide if it is the right solution. Before you even think about where to buy Cefaly , it would be wise to have a good understanding of how the latter works.
What exactly is Cefal?
Although the FDA classified the Cefaly as a transcutaneous electrical nerve stimulation (TENS) unit, it is more particularly an external trigeminal nerve stimulation (eTNS) unit. The facility of the Cefaly is similar to that of other neurostimulators being tested for migraine treatment. Given that the trigeminal nerve is associated with a migraine, it’s theorised that stimulation of the nerve is one of the natural remedies for migraine headache.
The gadget is available by prescription just and at this point is an out of pocket expenditure for patients. The expense of the gadget is $299 and $25 for a set of 3 multiple-use electrodes (each electrode is meant to be used 20 times). The device looks like a headband that is worn throughout the forehead with an electrode calling the forehead. The gadget is intended to be used for a 20-minute session, when each day, every day as a preventive treatment.
The FDA approval was based upon two research studies that revealed security and tolerability of the gadget, with the smaller sized of the two research studies showing a modest benefit in the decrease of days monthly with a migraine and less migraine medication usage than those who were using the placebo gadget.
This study was small, consisting of only 67 patients with an average of nearly seven migraine days per month. The research study found a statistically significant difference between the active device and placebo device with patients utilising the mobile gadget seeing a reduction of migraine days per month from nearly seven days per month to just under five days per month.1.
A more extensive survey study was performed of 2,313 migraine patients who leased the gadget for 40 days. This research study discovered that 54% of patients were satisfied with the device and willing to acquire it.2 In both studies, there were not any significant adverse occasions, and a lot of negative occurrences were small.
Where does Cefaly fit in for the management of a migraine?
At this moment, it is premature to make any definitive declarations about the long-lasting and sustained effectiveness of the gadget. Extra studies would be beneficial to provide more details concerning precisely what client demographics best reacted, and if the response is short-term or if there is a continual advantage.
Given that there are reasonably few adverse effects or significant potential repercussions, it may be a beneficial tool to have available for patients who are either reluctant to try other preventive treatments or patients who for other health reasons can not use other preventive procedures.
Thus far, there has been a tremendous public awareness of the accessibility of this device, and to me, that is the most exciting aspect of the Cefaly FDA approval. This reaffirms the message to clinicians and researchers that patients with migraine are in need of additional treatment alternatives and are somewhat receptive to new potential treatment choices.
Celfay’s efficiency will be only identified by time. However, its prospective long-lasting impact may be the generation of more conversation around a migraine and resulting in more investigation of other treatment modalities.
